tbuckley/cabot-search huggingface dataset:
AB1541-HPR INTER-RATER RELIABILITY OF THE ANKYLOSING SPONDYLITIS PERFORMANCE INDEX IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
Authors: S. Mink, K. Knak, J. Primdahl, C. Rasmussen
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Patients with axial spondyloarthritis (axSpA) are limited in daily activities due to spinal stiffness. Traditionally, functional ability in patients with axSpA has been assessed by the well-known Bath Ankylosing Spondylitis Functional Index (BASFI) questionnaire. During the past years, the objective Ankylosing Spondylitis Performance Index (ASPI) has emerged and has been shown to be intra-rater reliable and more responsive than the BASFI. So far, only one study has investigated the inter-rater reliability in patients with axSpA and it remains to be established in a Nordic country. <h3>Objectives:</h3> The objective was to investigate the inter-rater reliability of the ASPI test in patients with axSpA in a Nordic country. <h3>Methods:</h3> Patients with an axSpA confirmed diagnosis were recruited in a rheumatology outpatient clinic in Denmark. Two raters were trained in how to perform the test and tested the patients independently. The second rater did not have access to the scores from the first rater. The patients were randomly allocated in the order of raters. Patients were instructed to perform the ASPI test twice in a secluded room at the hospital with a 15-minute rest in between. Relative and absolute reliability were analyzed. <h3>Results:</h3> Fifty-two patients were included. The relative inter-rater reliability of the ASPI test was good to excellent (overall ASPI Inter Class Correlation (ICC) was 0.91, 95% CI 0.76-0.96). Patients performed the ASPI test faster at rater 2 (mean ± SD, 38.15 sec ± 12.16 sec) as opposed to rater 1 (40.92 sec ± 12.07 sec), a statistically significant reduction time of -2.77 sec ± 4.53 sec (p&lt;0.001). The Bland Altman plots demonstrated a learning effect on a group level but not on an individual level. <h3>Conclusion:</h3> In conclusion, the ASPI test showed a high level of relative reliability in Danish patients with axSpA. The absolute reliability of the ASPI test demonstrated a learning effect on a group level, but not on an individual level, and, thus, a familiarization trial is recommended in groups. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> René B. Jørgensen, University College Southern Denmark, Esbjerg and Haderslev, Denmark. <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS0704 SEPSIS OUTCOMES IN INDIVIDUALS WITH AND WITHOUT AUTOIMMUNE RHEUMATIC DISEASES: A POPULATION BASED STUDY
Authors: S. Piplani, V. Jelic, S. Kong, V. R. Bejugam, M. Sedaghati, N. Tanasijevic, D. Damania, J. Reet, M. Radulovic, M. Vukelic, B. Johnson, C. Tagoe
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Sepsis is a leading cause of mortality in hospitalized patients. Autoimmune rheumatic disease (ARD) patients have an elevated risk due to their immune dysfunction, and immunomodulating therapy. Diagnosing sepsis in ARD patients is challenging, as their immune dysfunction can mask symptoms. Delays in diagnosis and treatment contribute to increased mortality risk. This study aims to bridge knowledge gaps, comparing sepsis outcomes in ARD and non-ARD patients. <h3>Objectives:</h3> To explore sepsis outcomes in individuals with ARD compared to individuals without ARD, using a large database in the United States, the national inpatient sample (NIS) database <h3>Methods:</h3> The NIS database was queried from 2015 to 2019, with the principal diagnosis of Sepsis and secondary diagnosis was used to identify patients with Autoimmune Rheumatic Diseases combined using pre-verified ICD-10 Codes. Data was appended using latest health care cost and utilization project (HCUP). Univariate analysis with student t test and chi square was performed, and a multivariate regression model was used to generate odds ratio adjusting for hospital level confounders and various co-morbidities. P-value of &lt;0.05 was considered significant, and all the analysis was performed using STATA-MP v 14.2. <h3>Results:</h3> Among the 10,962,406 reported cases of sepsis in the United States in the NIS database, 417,884 were identified as having ARD. Sepsis patients with ARD demonstrated increased comorbidity burden (56.09% vs. 44.21% with charlson co-morbidity index ≥ 3, p &lt; 0.0001). Various chronic conditions, including hypertension, diabetes, CHF, obesity, CKD, thyroid disease, and liver disease, were more frequent in sepsis patients with ARD all with p &lt; 0.0001. <h3>Conclusion:</h3> Contrary to prior beliefs, patients with ARDs, despite having more comorbidities, exhibited lower mortality rates, shorter hospital stays, and fewer complications when suffering from sepsis compared to those without ARD. The findings suggest that heightened awareness, regular follow-ups, and distinct immune responses in ARD patients may contribute to these improved outcomes. The study was limited as data used was retrospective, there is no account of disease stage and medications use cannot be tracked. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1582-HPR “ LIVING YOUR BEST LIFE, A SIMPLE GUIDE TO LIVING WITH ARTHRITIS”, DESIGN AND DEVELOPMENT OF A BOOKLET BASED ON THE SIX PILLARS OF LIFESTYLE MEDICINE
Authors: U. Martin, N. O ’keeffe, B. Irudayaraj, P. Mcsharry, L. Reynolds, P. Goff, P. Boyd
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Health systems globally are facing huge challenges to deal with the ever-growing numbers of non-communicable diseases (NCD's), the majority of which are lifestyle associated. In the Irish context, 1.07million people have one or more chronic diseases, 76% of deaths are attributed to chronic disease and there is a 4% increase in chronic disease each year (Healthy Ireland Survey 2015: Summary of findings, 2021).Patients with RA have co-morbidities such as cardiovascular disease and hypertension (Pranata et al 2020). Lifestyle choices such as smoking have been shown to reduce treatment response (Aimer et al 2020). Cornelissen et al (2021) exploring what matters to patients with RA when facing medical decisions, patients emphasised the value of healthy lifestyle and keeping up their physical fitness. <h3>Objectives:</h3> To produce an evidence based booklet to support the patient and the clinician to incorporate lifestyle medicine into rheumatology clinical care. <h3>Methods:</h3> Funding was secured via a nursing bursary award. The project lead, brought together a team of seven experts including nursing, physiotherapy, occupational therapy, dietetics, substance misuse, health coaching and patients. The group collaborated with a design expert to conceptualize the booklet, key messages, tone and brand. Each healthcare professional created content for each lifestyle pillar according to their expertise. Patient feedback informed change through the process. <h3>Results:</h3> The booklet facilities lifestyle changes with a range of tools to activate patient participation to identify and address small changes in each pillar and their relationship with arthritis. Bridges self-management tools and language is a theme through all six pillars offering person centred techniques to facilitate and guide individual behaviour change meaningful to each patient. <h3>Conclusion:</h3> Lifestyle changes can have a significant impact on health and arthritis. By using the principles of lifestyle medicine patients have the potential to adapt and sustain positive lifestyle changes and live their best life with arthritis. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> RCSI Faculty of Nursing and Midwifery. <h3>Disclosure of Interests:</h3> Una Martin Abbvie Ireland, Nicole O'Keeffe: None declared, Bindu Irudayaraj: None declared, Patsy McSharry: None declared, Louise Reynolds: None declared, Paul Goff: None declared, Peter Boyd: None declared.
A phase 1 study of SHR-A1912, a CD79b targeted antibody-drug conjugate (ADC), in patients (pts) with B-cell non-Hodgkin lymphoma (B-NHL).
Authors: Zengjun Li, Yang Xie, Shuqin Ni, Hui Zhou, Junmin Chen, Pinfang Huang, Wei Yang, Li Zheng, Liqun Zou, Yike Wang, Yiming Liu, Dahua Ma, Wenjun Mao, Jun Zhu, Yuqin Song
Journal: Journal of Clinical Oncology (2024)

7064 Background: CD79b is an attractive therapeutic target for B-NHL. SHR-A1912 is a novel ADC containing an anti-CD79b monoclonal antibody conjugated to the DNA topoisomerase I inhibitor. Here, we present results of the dose-escalation (D-ESC) and dose-expansion (D-EXP) parts of a first-in-human phase 1 study of SHR-A1912 in B-NHL. Methods: Pts with histologically confirmed B-NHL that had failed to respond to or had progressed after ≥1 prior anti-cancer therapy were enrolled. The D-ESC part commenced with accelerated titration at 0.1 and 0.3 mg/kg and then switched to an i3+3 scheme at escalated doses starting from 0.6 mg/kg (Q3W, IV). In the D-EXP part, additional pts were enrolled to selected doses (approximately 10–12 pts in total per dose level). Primary objectives were to assess the safety and tolerability of SHR-A1912 and determine the RP2D. Results: As of Nov 7, 2023, 49 pts were enrolled (n=1, 1, 7, 3, 13, 13, and 11 in the 0.1, 0.3, 0.6, 1.2, 1.8, 2.7, and 3.6 mg/kg dose cohorts), including 33 pts with diffuse large B-cell lymphoma (DLBCL), 12 with follicular lymphoma (FL), and 4 with marginal zone lymphoma (MZL). Pts had received a median of 2 lines of prior treatment (range, 1–9). DLTs occurred in 3 pts during D-ESC (grade 4 decreased neutrophil count lasting ≥3 days in 0.6 and 3.6 mg/kg cohorts, 1 pt for each; grade 3 pneumonia in 2.7 mg/kg cohort, 1 pt). The 1.8, 2.7, and 3.6 mg/kg cohorts were expanded. Overall, grade ≥3 treatment-related adverse events occurred in 20 (40.8%) pts, with the most common (≥20%) being decreased neutrophil count. 41 pts with baseline target lesions had at least one post-baseline assessment; ORR was 56.1% (95% CI, 39.8–71.5), and 6-mo DoR rate was 62.7% (95% CI, 26.7–84.8). As for subtypes, ORR was 51.9% in pts with DLBCL (57.1% and 77.8% in the 2.7 and 3.6 mg/kg cohorts, respectively), 63.6% in pts with FL, and 66.7% in pts with MZL (Table). The mean half-life of conjugated antibody ranged from 4.7 to 5.3 days for pts in the 1.8–3.6 mg/kg cohorts, with volume of distribution close to human plasma volume. The plasma exposure of free toxin was low, with the molar ratio of toxin/conjugated-antibody &lt;1%, and no accumulation was observed. Conclusions: SHR-A1912 was tolerable up to 3.6 mg/kg and had promising anti-tumor activity in pts with previously treated B-NHL, supporting further investigations of SHR-A1912. Clinical trial information: NCT05113069 . [Table: see text]
POS1360 DO ROUTINE RADIOGRAPHS OF HANDS AND FEET IN PATIENTS WITH CLINICALLY SUSPECT ARTHRALGIA HAVE DIAGNOSTIC OR PROGNOSTIC VALUE? A LARGE LONGITUDINAL STUDY
Authors: Q. A. Dumoulin, A. H. M. Van der Helm – van Mil, H. W. Van Steenbergen
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Traditionally, conventional radiographs of hands and feet in rheumatoid arthritis are used to depict structural joint damage. This is also commonly done in symptomatic patients at risk for RA (clinically suspect arthralgia (CSA)), however the rationale for this is questionable since the prevalence and implications of radiographic joint damage in this disease phase are unknown. <h3>Objectives:</h3> We therefore aimed to investigate the prevalence of radiographic joint damage in CSA and its progression over time. <h3>Methods:</h3> 749 symptomatic patients at risk for RA development from our observational CSA cohort were followed until development of inflammatory arthritis (IA) or during 2 years follow-up. Radiographs of hands and feet were conducted at maximum four points in time (baseline, 4, 12 and 24 months or upon development of IA). Radiographic joint damage of in total 1,494 radiographs was evaluated in three ways; erosive disease according to the radiologist, according to the Sharp van der Heijde Scoring method (SHS) and erosive disease specific for RA according to the EULAR/ACR 2010 RA-criteria. Prevalence and progression of radiographic joint damage were described during two years follow-up or until development of IA, for the total cohort and stratified for ACPA (anti-citrullinated protein antibody)-status. Progression of &gt;5 SHS-points was considered as the minimal clinically important difference (MCID). The predictive value of baseline SHS for IA-development was analysed via Cox regression analyses adjusted for age. <h3>Results:</h3> According to the radiologist, 1.7% of patients had erosive disease at first presentation (Figure 1A). The median erosion SHS was 1 (interquartile range (IQR) 0-1) and similar for ACPA-positive and ACPA-negative patients (both 0 (0-1), p=0.45). 2.5% of patients had erosive disease as defined by the EULAR/ACR 2010 criteria (Figure 1B). Radiographic progression greater than the MCID was rare (4%) in CSA-patients (Figure 1C), regardless of ACPA-status or IA-development. Baseline SHS was not predictive for IA-development (hazard ratio 1.02 (95% confidence interval 0.97;1.07)), also not in ACPA-subgroups or when studying only SHS-erosion scores. <h3>Conclusion:</h3> At CSA-onset, radiographic erosions are rare. Erosion scores and SHS-scores are not predictive for IA development. Moreover, radiographic progression over time is scarce. Therefore, for clinical practice, routinely made radiographs such as in RA, can be omitted in the at-risk stage of CSA. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1620-HPR CHANGE IN THE UTILITY OF ANTINUCLEAR ANTIBODIES (ANA) FOLLOWING THE IMPLEMENTATION OF ANALYTICAL REQUEST BASED ON PATIENT PROFILE
Authors: I. De la Morena Barrio, P. Olivan, L. C. Charca Benavente, D. Bedoya Sanchis, J. J. Sanmartín Martinez, D. Fernandez-Lozano, N. Costas Torrijo, P. Trenor Larraz, E. Rodriguez Borja
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> The diagnosis of autoimmune diseases has increased, reflected in a rise in the number of ANA determinations per year and referrals to the rheumatology service (RS) for the assessment of positive results. It was estimated that 70% of diagnoses are based on laboratory tests, but if the indication for ANA corresponds to a reasonable pretest probability, the likelihood of obtaining valuable post-test information increases, and vice versa. The indiscriminate request for ANA leads to system overload and increased expenses, undermining the value of the results. <h3>Objectives:</h3> To compare the employability and cost of ANA determinations before and after the implementation of a tool for requesting analyses based on the patient's clinical profile in Primary Care (PC). <h3>Methods:</h3> Retrospective, longitudinal study where two study periods are established: the year 2021 (24-month follow-up) and the year 2023 (follow-up for the year 2023). The following data are collected: number of ANA requests from PC, number of referrals to RS due to positive results, patient profile, clinical manifestations for which tests are requested, final diagnosis, discharges, and follow-up time. The expenditure on ANA determinations, the appropriateness of the request in referred patients, and the changes in these parameters before and after the tool's implementation in 2022 are analyzed. <h3>Results:</h3> There is an upward trend in the number of ANA requests from PC from 2019 to 2021, with a rising expenditure trend of 2.28%. Subsequently, this trend is reversed (Table 1), calculating a savings, solely in ANA determinations, of 36,120.96 euros in 2022 and 2023. In 2021, 134 patients were referred to RS due to positive ANA, at a time when there were 3 rheumatologists, and 123 in 2023, when there were 5, showing a decrease in the referral rate to rheumatologists, being 44.6 in 2021 and 24.6 in 2023. Table 2 presents the comparison of variables from patients referred to RS in both periods. <h3>Conclusion:</h3> The new tool has facilitated a reduction in expenses for ANA determinations and referrals to the RS, and improving pretest appropriateness for those referred to the RS. In 2023, the diagnosis of rheumatoid arthritis, other types of arthritis, and polymyalgia rheumatica decreased, aligning with three of the clinical profiles defined by the tool and adjusting suspicion-determination. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1679-PARE THE IMPACT OF HAND FUNCTION IMPAIRMENT ON DAILY LIFE IN DUTCH PATIENTS WITH SYSTEMIC SCLEROSIS - A QUALITATIVE STUDY
Authors: N. El Bardai, M. Greveling, M. R. Schriemer, S. Dittmar, C. H. M. Van den Ende, L. Tweehuysen, J. Spierings
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Systemic sclerosis (SSc) is a chronic multiorgan disease that can impact quality of life tremendously. Hand function impairment can potentially limit daily activities in different ways [1]. A Dutch cross-sectional study in 650 SSc patients showed that 28% of the respondents mentioned reduced hand function as an unmet need in SSc care [2]. In order to improve patient support, further research is needed to better understand the impact of hand function impairment in SSc. <h3>Objectives:</h3> The aim of this study was to gain a deeper understanding of the various aspects of hand function impairment in the daily lives of Dutch people with SSc and to explore their unmet care needs. <h3>Methods:</h3> Adult patients with SSc were selected from the outpatient clinic and day care unit from the University Medical Centre Utrecht. Face to face semi-structured interviews were held. Interviews were transcribed verbatim and coded. Additional information on hand function impairment were obtained by hand examination, the modified Hand Mobility in Scleroderma (mHAMIS), Cochin Hand Function Scale (CHFS) and modified Rodnan Skin Score (mRSS). <h3>Results:</h3> We included 18 patients, compromising 15 female patients (83%) and 3 male patients (17%). The median (IQR) age was 59 (53-65) years. The median (IQR) mRSS was 8 (5-15) points and the median (IQR) CHFS was 36 (25-47) points. The most reported complaints were pain in the hands after activity, loss of sensitivity and of manual strength. We identified 5 themes and 4 sub-themes after analysis of the interviews: types of hand function impairment, impact of hand function impairment (on daily life, (un)paid work, mental health, and relationships), management of hand function impairment, expectations and unmet care needs (see Table 1). <h3>Conclusion:</h3> This study contributes to better understanding of patients' experiences with hand function impairment on different aspects of daily life and experiences in healthcare. We identified unmet care needs, such as lack of routine monitoring of hand function and lack of awareness of hand impairment among health care providers. <h3>REFERENCES:</h3> [1] Van Leeuwen NM, Ciaffi J, Liem SIE, et al. Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. Rheumatology (Oxford). 2021 Aug 2;60(8):3646–55. [2] Stöcker JK, Vonk MC, van den Hoogen FHJ, et al. Room for improvement in non-pharmacological systemic sclerosis care? — a cross-sectional online survey of 650 patients. BMC Rheumatol. 2020 Dec 31;4(1):43. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1579-HPR COMPARISON OF TRIGGER POINT INJECTION APPLICATION METHODS IN MYOFASCIAL PAIN SYNDROME IN PATIENTS WITH FIBROMYALGIA SYNDROME
Authors: M. Ş. Elbasti, S. Baglan Yentur
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Treatment of Fibromyalgia Syndrome (FMS) aims to inactivate the trigger point, relieve pain and eliminate aggravating factors. Recently, the use of ultrasound (US) has been recommended to minimize the complications that may be encountered in trigger point injection and to perform an effective injection. <h3>Objectives:</h3> This study was aimed to compare the efficacy of blinded and US-guided trigger point injection into the trapezius muscle in individuals with FMS. <h3>Methods:</h3> 75 patients with FMS were included in the study. After the patients were randomly divided into two groups, one group underwent US-guided trigger point injection. The second group was practiced blinded trigger point injection. Both groups were given the same home exercises (stretching and posture exercises related to the trapezius and pectoral muscles). Patients were re-evaluated at 1 month after treatment to assess the efficacy of the treatments. Fibromyalgia Impact Questionnaire (FEA), Visual Analog Scale (VAS), Beck Anxiety Inventory (BAI) and Neck Disability Index were used to evaluate function, pain, anxiety and disability of neck, respectively. <h3>Results:</h3> The study was completed with 60 patients. There was no statistically significant difference between the demographic variables of the two groups (p&gt;0.05). When US-guided and blinded trigger point injections were compared, a significant difference was observed in neck disability (p=0.041). Significant differences were observed in both groups in all parameters evaluated in pre and post-treatment evaluations (p&lt;0.05). <h3>Conclusion:</h3> USG-guided trigger point injection had positive effects on pain, function, anxiety and neck pain in FMS patients. USG-guided trigger point injection may be recommended in clinics to improve symptoms of the disease. <h3>REFERENCES:</h3> [1] Taheri N, Rezasoltani A, Okhovatian F, Karami M, Hosseini SM, Mohammadi HK. Quantification of dry needling on myofascial trigger points using a novel ultrasound method; A study protocol. J Bodyw Mov Ther. 2016 Jul;20(3):471-6. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>